Peroxiredoxin 4 in Alveolar Macrophages: A Novel Target for the Treatment of Silicosis Fibrosis

Jiawei Zhou,Ying Bai,Jianqiang Guo,Yafeng Liu,Xin Zhang,Chao Liang,Wenyang Wang,Yingru Xing,Jing Wu,Dong Hu
DOI: https://doi.org/10.2139/ssrn.4194647
2022-01-01
Abstract:Abstract Silicosis is an occupational disease with the highest morbidity and mortality, and no specific medicine or recognized cure is available. Here, for the first time, we identified peroxiredoxin 4 (PRDX4) as a tissue-specific regulator of alveolar macrophages (AMs) in silicosis patients. We construct mouse models of early silicosis with self-repair and silicosis with systemic inhibition or conditional knockdown of PRDX4. Mechanistically, PRDX4 is selectively and highly expressed in AMs of silicosis patients and mice, which activates AMs through AKT/NF-κB pathway, thus promoting the transformation of pulmonary epithelial cells and fibroblasts. Functionally, systemic administration of a PRDX4 inhibitor (Conoidin A) significantly improves pulmonary self-repair in early silicosis mice. Interestingly, when knocking down PRDX4 of AMs by AAV virus vector, it not only prominently prevents the progression of crystalline silica (CS)-induced pulmonary fibrosis in mice, but also exhibits lower side effects. Taken together, these findings highlight PRDX4 as a novel target of AMs in regulating pulmonary inflammation and fibrosis, and targeted inhibition of PRDX4 in AMs may support a potential therapeutic strategy for silicosis.
What problem does this paper attempt to address?